Increasing Macrolide and Fluoroquinolone Resistance in Mycoplasma genitalium

Escalating resistance to azithromycin and moxifloxacin is being reported for Mycoplasma genitalium in the Asia-Pacific region. Analyzing 140 infections, we found pretreatment fluoroquinolone-resistance mutations in parC (13.6%) and gyrA (5%). ParC S83 changes were associated with moxifloxacin failur...

Descripción completa

Detalles Bibliográficos
Autores principales: Murray, Gerald L., Bradshaw, Catriona S., Bissessor, Melanie, Danielewski, Jennifer, Garland, Suzanne M., Jensen, Jørgen S., Fairley, Christopher K., Tabrizi, Sepehr N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Centers for Disease Control and Prevention 2017
Materias:
Dispatch
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5403035/
https://www.ncbi.nlm.nih.gov/pubmed/28418319
http://dx.doi.org/10.3201/eid2305.161745
Descripción
Sumario:Escalating resistance to azithromycin and moxifloxacin is being reported for Mycoplasma genitalium in the Asia-Pacific region. Analyzing 140 infections, we found pretreatment fluoroquinolone-resistance mutations in parC (13.6%) and gyrA (5%). ParC S83 changes were associated with moxifloxacin failure. Combined macrolide/fluoroquinolone-resistance mutations were in 8.6% of specimens, for which recommended therapies would be ineffective.

Ejemplares similares